Pure Global
NCT06390709

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

Scipher Medicine·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Rheumatoid Arthritis
Drug/Device/Intervention
Lab Collection Only
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Scipher Medicine
Location
Whittier, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 08, 2024
End date
Dec 31, 2025
Enrollment
1100 participants
Primary outcome

The rate of MSRC to predict the patients response

Summary

Prospective, multi-center-observational study conducted within the US, collecting patient
 samples for research and development to train, test, and validate precision medicine
 classifiers. These molecular signature response classifiers (MSRC) aim to predict response
 status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis
 (RA).

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06390709
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06390709 through Pure Global AI's free database. This phase not specified trial is sponsored by Scipher Medicine and is currently Recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 1100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.